Leucovorin’s Fast Track: Is It the Right Move?
In a surprising development, Health Secretary Robert F. Kennedy Jr. may soon grant President Trump a significant policy win. The Food and Drug Administration (FDA) is working with GSK to quicken the approval of leucovorin, a medication used for an autism-related condition.
The FDA’s decision allows it to skip the usual lengthy processes that come with drug approvals, such as updating labels for generics or conducting new clinical trials. GSK aims to submit its application quickly, and the FDA typically takes four to six months to review such requests. In some cases, they may even act faster, according to Giuseppe Randazzo, a representative from the Association for Accessible Medicines.
This expedited process might give doctors more reasons to prescribe leucovorin for cerebral folate deficiency, a metabolic issue linked to neurological symptoms associated with autism. While Kennedy aligns with Trump’s “Make America Healthy Again” initiative, experts caution that the evidence supporting this medication’s effectiveness is still lacking.
Dr. Ameet Sarpatwari, a researcher at Harvard Medical School, describes the label change as potentially superficial. The drug, which counteracts harmful cancer treatment effects and costs around $34 for 30 pills, may gain better insurance coverage if its label changes.
Rising Demand: What’s Behind It?
The demand for leucovorin surged after a CBS report highlighted its potential benefits for a nonverbal child and again after Trump endorsed its use. Dr. Larry Gray, a pediatric expert, has noticed an uptick in inquiries from parents eager for this treatment. However, it currently isn’t FDA-approved for autism treatment, leading institutions like Lurie Children’s Hospital to limit its use to clinical trials.
Kennedy recently labeled the increasing autism rates—currently at 1 in 31 children—an epidemic, promising to seek answers for its causes and potential treatments.
At a White House event, Kennedy, Trump, and other health officials endorsed leucovorin while cautioning against the use of Tylenol in pregnant women, linking it to autism. Many experts criticized this warning as lacking a strong scientific basis.
Navigating Unusual Regulations
The FDA is utilizing an obscure regulation to accelerate GSK’s application. This rule allows updates based on their analysis of case studies from the past few years instead of conventional lengthy trials. GSK had previously marketed leucovorin until 1997, and generic versions are available, making it accessible to many.
When GSK’s application gets approved, generic manufacturers must comply with the new label—a process that typically takes much longer and involves extensive consultations.
According to Aaron Kesselheim, a professor of medicine at Harvard, this approach seems unusual and raises questions about whether the FDA is adhering to sufficient standards of evidence.
What’s the Evidence So Far?
Experts say the data on leucovorin is limited. Dr. Andy Shih, from Autism Speaks, points out that previous studies with small sample sizes only hint at potential benefits for a minor group of autistic children. Dr. Karam Radwan advocates for larger trials to confirm efficacy.
Currently, three mid-stage trials are examining a liquid form of leucovorin aimed at treating language impairments in children with autism. These studies involve collaborations with organizations like the National Institutes of Health and the Department of Defense. Results are expected by December, but comprehensive trials will take time, and the FDA’s current method does not involve new trials.
Dr. Radwan emphasizes the need for solid scientific backing before making treatment changes. Until more robust evidence emerges, caution is key.
For further reading, you can check out resources like the FDA and recent studies from Autism Speaks.
Source link
news,traffic,weather,sports,classifieds,cars,jobs,homes,television,radio,salt lake,utah,local,Health,Politics,Science,Business
